Drugs.com - Pharma Industry News

Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors

MONDAY, March 3, 2025 -- For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2 inhibitor sotagliflozin is associated with a significantly reduced...

Mar 3, 2025 - 18:16
 0
Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors
MONDAY, March 3, 2025 -- For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2 inhibitor sotagliflozin is associated with a significantly reduced...
Read More

Tags:

Previous Article

Ultra-Rapid Molecular-Genetic Assays Feasible for Tumor Classification During Su...

Next Article

How Metrea hopes to grow the private air refueling market

Related Posts

At 10 Years, Roux-en-Y Gastric Bypass Superior for Patient Excess BMI Loss

At 10 Years, Roux-en-Y Gastric Bypass Superior for Pati...

Feb 24, 2025  0

Childhood Physical Activity, Screen Time Linked to Teens' Stress, Depressive Symptoms

Childhood Physical Activity, Screen Time Linked to Teen...

Feb 20, 2025  0

2022 to 2023 Saw Decrease in Rate of Drug Overdose Deaths in United States

2022 to 2023 Saw Decrease in Rate of Drug Overdose Deat...

Feb 21, 2025  0